When a dementia prevention trial announces it has finished enrolling participants, that is a recruitment milestone, not a result — the trial has not shown whether the drug works. The AHEAD 3-45 study, a Phase 3 trial testing the anti-amyloid antibody lecanemab in cognitively normal people with elevated brain amyloid, completed enrollment in October 2024, and as of September 2026 its ClinicalTrials.gov record still shows no study results posted.
That gap between headline and evidence matters for readers weighing their own risk. Enrollment news tells you a trial is on schedule and that scientists could find enough qualifying volunteers. It says nothing yet about whether the treatment prevents dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Register through ClinicalTrials.gov’s official page — Use this page to review requirements and register directly.
- View the official study record on ClinicalTrials.gov — Use this record to verify the study status and eligibility details.
Table of Contents
- What AHEAD 3-45 is actually testing
- Why "fully enrolled" gets mistaken for good news about the drug
- What these drugs are — and are not — approved for
- What a reported prevention result looks like
- What to do while the drug trials run
- Frequently Asked Questions
What AHEAD 3-45 is actually testing
AHEAD 3-45 asks whether lecanemab, an antibody that clears amyloid protein from the brain, can slow cognitive decline in people who have no symptoms but already show amyloid buildup — a state researchers call preclinical Alzheimer's. It is a public-private partnership between the NIH's National Institute on Aging–funded Alzheimer's Clinical Trial Consortium, Eisai, and Biogen, according to Eisai's enrollment announcement. The study is really two trials in one. The A45 trial enrolls people with elevated amyloid and measures cognitive change on a composite test called the PACC5.
The A3 trial enrolls people with intermediate amyloid and measures change on amyloid PET scans. Volunteers were screened with blood tests, cognitive testing, amyloid PET, MRI, and tau PET. Both trials measure their primary endpoints only after 216 weeks — about four years — of blinded treatment. Per the trial's published design, that means results cannot arrive until roughly 2028–2029 no matter how encouraging the enrollment news sounds.
Why "fully enrolled" gets mistaken for good news about the drug
Enrollment milestones generate press releases, and press releases generate headlines that can read like progress toward a proven treatment. But a trial that finishes enrolling has simply reached its planned size. The participants are still split between drug and placebo, nobody involved knows who is receiving which, and the outcome data are still accumulating. The same pattern applies to Eli Lilly's parallel prevention trial, TRAILBLAZER-ALZ 3, which tests donanemab in preclinical Alzheimer's and finished enrolling in August 2024.
Researchers screened 63,124 people aged 55–80 and enrolled 2,196 based on a plasma p-tau217 blood test, as reported in Alzheimer's & Dementia. Only about 3.5% of screened volunteers qualified. That funnel is genuinely informative — it shows blood-based biomarker screening works at scale, which matters for how future prevention trials and eventually clinics might identify at-risk people. It just is not evidence that donanemab prevents dementia.
What these drugs are — and are not — approved for
Lecanemab and donanemab are FDA-approved, but only for symptomatic early Alzheimer's disease: people who already have mild cognitive impairment or mild dementia with confirmed amyloid. Their use in healthy, symptom-free people exists only inside these blinded trials. That distinction is the core of what enrollment news means.
A drug that slows decline in people with symptoms may or may not delay dementia when given years earlier, and the side-effect trade-offs differ when the person taking the drug feels entirely well. Both prevention trials remain blinded and event-driven, so completed enrollment cannot be read as evidence of prevention benefit in healthy adults. Anyone offered anti-amyloid treatment outside a trial while cognitively normal should understand that no efficacy data support that use yet.
What a reported prevention result looks like
For contrast, the U.S. POINTER trial shows what finished prevention evidence looks like. Its 2,111-participant randomized trial found that a structured lifestyle program — exercise, diet, cognitive and social activity, and health monitoring — improved global cognition versus a self-guided program over two years, with results published in JAMA on July 28, 2025 and announced by the Alzheimer's Association.
Note the difference in the language: POINTER reports a measured outcome in a completed comparison, with a journal publication attached. AHEAD 3-45 and TRAILBLAZER-ALZ 3 announcements describe screening numbers and enrollment counts. Reading trial news, that is the fastest tell — look for an outcome, a comparison group, and a publication, not a participant tally. Lifestyle intervention is, to date, the only prevention approach with a reported randomized-trial benefit.
What to do while the drug trials run
A practical way for adults 55–80 to handle prevention-trial coverage between now and the readouts: When AHEAD 3-45 does read out, the result will apply to people who matched its entry criteria — cognitively normal, with amyloid confirmed by blood test and PET imaging — so a screening conversation with a clinician is the first step toward knowing whether any eventual approval would apply to you.
- Treat enrollment announcements as feasibility news; the earliest anti-amyloid prevention results are expected around 2027–2029.
- Check the trial's ClinicalTrials.gov results tab before assuming a headline means new evidence — AHEAD 3-45 is NCT04468659.
- Act now on the approach that has reported benefit: structured exercise, diet, cognitive and social engagement, and regular health monitoring, per the POINTER findings.
- If you want to contribute to the answer rather than wait for it, prevention trials recruit continuously; ask a memory clinic or academic medical center about studies currently screening.
Frequently Asked Questions
When will the AHEAD 3-45 trial report results?
Its primary endpoints are measured after 216 weeks of blinded treatment, so results are expected around 2028–2029; the ClinicalTrials.gov record showed no posted results as of September 2026.
Can I get lecanemab or donanemab to prevent Alzheimer's if I have no symptoms?
No. Both drugs are FDA-approved only for symptomatic early Alzheimer's disease; prevention use exists only within blinded clinical trials.
Has any dementia prevention approach shown benefit in a completed randomized trial?
Yes — the U.S. POINTER trial reported in JAMA in July 2025 that a structured lifestyle program improved global cognition over two years versus a self-guided program.
